1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. (23rd October 2018) - Gettinger, S; Beck, T; Yang, X; Telivala, B; Morgensztern, D; Velcheti, V; Ramalingam, S S; Schalper, K; Dajee, M; Ranck, A; Yang, R; Spigel, D R